Can You Buy Peptides Over the Counter? What's Legal, What Needs a Prescription & What's Grey-Market

"Over the counter" is not a property of a molecule. It is a fact about a jurisdiction's medicines register, and the peptides people ask about fall into four categories with four different answers. Only one category contains a genuine yes.

Sorting a compound into the right category is the whole exercise, and it takes about two minutes once you know which four documents to read. The statutory machinery is in compounding pharmacy versus research peptide, the dated record in the FDA peptide regulation timeline, and the jurisdiction-by-jurisdiction snapshot in are peptides legal.

Can you buy peptides over the counter?

Almost never, and the exceptions are jurisdictional rather than chemical. Of the four categories a peptide can occupy, three are prescription-only or unlawful to sell for human use: approved prescription medicines, compounds with a lawful compounding route through one of three statutory prongs, and unapproved compounds sold as research chemicals. The fourth is genuinely over the counter — Selank and Semax are registered Russian nasal preparations dispensed without prescription — and that status belongs to Russia's register, not to the peptides.

Most confusion in this market comes from treating the question as though it had one answer. It has four, they point in different directions, and a compound's position on one axis says nothing about its position on another. A peptide can hold a marketing authorisation in one country, be an unapproved new drug in another, sit on an FDA list that blocks compounding, and be prohibited in sport, all at once.

This page states what published documents and registers say. It is legal information, not legal advice, it does not address any individual's position in any jurisdiction, and anything touching your own circumstances belongs with a qualified professional. Nothing here explains how to obtain an unapproved drug.

What are the four categories, and which answer does each get?

Four categories, four answers, and only one "yes". Approved prescription medicines need a prescriber. Lawfully compoundable substances also need a prescriber, because compounding is a prescription activity. Unapproved compounds sold as research chemicals are not over-the-counter products at all — they are unapproved new drugs when sold for human use. Registered over-the-counter medicines exist, and in this corpus that means two Russian nasal preparations from one Moscow institute.

Notice which category the great majority of the compounds on this platform sit in. Category 3 is not a lighter version of category 1; it is a different legal object, and the phrase "over the counter" does not describe it in any jurisdiction. A shop that takes a card payment is not a counter in the regulatory sense.

Which peptides are approved prescription medicines?

Fewer than the market implies, and each approval is for a narrow indication rather than for a molecule. In the United States tesamorelin, bremelanotide, afamelanotide, elamipretide, semaglutide, tirzepatide and oxytocin are approved medicines. Mazdutide is approved only in China, under two NMPA authorisations from June and September 2025. All of them require a prescriber, and none of them is available over the counter anywhere in this record.

Read the indication column rather than the approval column, because an approval is for a population and a purpose, not for a molecule. Bremelanotide's label carries FDA's own Limitations of Use: it is "not indicated for treatment of HSDD in postmenopausal women or in men," and "not indicated to enhance sexual performance." That second sentence excludes most of what the compound is bought for.

Which peptides can a pharmacy lawfully compound, and does that make them over the counter?

Very few, and no. Under 21 U.S.C. § 353a(b)(1)(A) a bulk substance used in 503A compounding must comply with an applicable USP or NF monograph, be a component of an FDA-approved drug, or appear on FDA's 503A bulks list — a list holding six substances, none of them a peptide. Gonadorelin qualifies on the first prong, tesamorelin and sermorelin on the second, oxytocin on both. Compounding is a prescription activity, so satisfying a prong changes nothing about the counter.

One honest caveat travels with sermorelin. Both Geref approvals were formally withdrawn in 2009, and we found no FDA document expressly resolving whether a withdrawn approval still satisfies the component prong. The 503B footnote implies the agency's answer; the final inferential step is not spelled out anywhere we could locate.

Even the lawful route carries a limit stated by FDA itself: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed." Qualifying under a prong is a statutory pathway, not an efficacy endorsement, and it is not a licence for a vial bought online.

What is a peptide sold as a research chemical?

An unapproved new drug, when it is sold for human use. Most peptides sit here, and for three distinguishable reasons rather than one. Some are on FDA's active Category 2 list, blocked pending evaluation — of its 14 substances, the peptides are GHRP-2, GHRP-6, ipamorelin acetate and kisspeptin-10. Some were nominated and then withdrawn by their nominators, which is procedural rather than a clearance. Most were never nominated, so FDA has never looked.

FDA's own sentence for the second table is the one most often misread: "This list of bulk drug substances previously in category 2 of the interim policies were withdrawn by the nominators." A withdrawal is not a clearance, and being absent from a list is not permission. A compound nobody nominated sits in exactly the same compounding position as one FDA examined and flagged.

The July 2026 advisory meeting changed nothing here either, and it is widely reported as though it had. FDA staff recommended against all seven substances reviewed on 23 and 24 July 2026, and the committee overrode that recommendation six times — BPC-157 8–6–1, KPV 8–6–1, TB-500 8–6–1, MOTS-c 7–5–2, Semax 8–5–1, Epitalon 7–4–1, with emideltide rejected 6–7–1. FDA published no minutes or transcript, so every tally is press-derived. An advisory vote is not an agency action, and nothing has been added to any list.

Does "research use only" labelling make a sale lawful?

No, and FDA has tested that proposition on a named seller. The agency "has warned companies that have illegally sold unapproved drugs... falsely labeled 'for research purposes' or 'not for human consumption.' These products have been sold directly to consumers for human use." The worked example is the warning letter to Xcel Research LLC, 10 December 2024, naming seven products including sermorelin and holding them to be unapproved new drugs under sections 505(a) and 301(d) of the Food, Drug and Cosmetic Act.

The reasoning is what makes that letter generalisable rather than a one-off. The products carried labelling reading "FOR RESEARCH USE ONLY" and "NOT INTENDED FOR HUMAN USE," and FDA held them to be unapproved new drugs anyway, because website evidence established human intended use. Intended use is established by evidence about how a product is presented and sold, not by the words printed on the vial. A disclaimer sitting beside dosing guidance, testimonials or before-and-after imagery does not describe the transaction it accompanies.

Sermorelin is the compound FDA chose to demonstrate this with, which is the sharpest possible illustration of the category system on this page. The same molecule sits in category 2 and category 3 simultaneously, depending entirely on who is supplying it and how. One route is a lawful prescription activity; the other has a warning letter attached.

Note the boundary of what that record establishes. The enforcement here runs against sellers, through warning letters, notices of opportunity for hearing and infringement notices. This page does not address the position of a purchaser in any jurisdiction, because the documents do not.

Which peptides genuinely hold over-the-counter status?

Two in this corpus, both in Russia, both from the same Moscow institute. Selank is registered with Russia's Ministry of Health under certificate ЛП-№(010951)-(РГ-RU), held by JSC INPC "Peptogen" of Moscow, as a 0.15% nasal drop in a 3 mL bottle, ATC code N05BX, and it is dispensed without prescription — Peptogen states it became an over-the-counter medicine on 2 August 2017. Semax holds certificate ЛП-№(009449)-(РГ-RU), dated 26 March 2025, as 0.1% and 1% nasal drops, ATC N06BX.

We could not verify the original year of first registration for either compound. The state register carries only the current, re-issued certificates under the EAEU format, and the years circulating online are not traceable to a primary source, so we are not printing one.

A national registration is a real regulatory fact and it is not the same as the evidence base behind it. Selank's four published patient trials all used a benzodiazepine comparator and none included a placebo arm; FDA's own reviewers concluded there is "insufficient evidence of effectiveness to support use of semax (free base) or semax acetate for cerebral ischemia, migraine, or trigeminal neuralgia." Over-the-counter status answers a question about supply, not about effect.

Why is "over the counter" a fact about a jurisdiction rather than a molecule?

Because it is created by a register, and registers are national. Selank is an over-the-counter medicine in Russia and an unapproved new drug in the United States, sitting in FDA's "bulk drug substances nominated but withdrawn" table on the page current 22 April 2026 with no USP monograph and no component status. Nothing about the molecule differs between those two sentences. Everything about the paperwork does.

Four agencies outside the United States have published findings that illustrate the same point from the enforcement side, all of them on melanotan II. Ireland's HPRA stated on 10 August 2023 that it is "not authorised by the HPRA or any medicines regulator to treat any condition," removing more than 500 listings between July 2022 and June 2023. The MHRA, in FOI response 24/274 of 17 April 2024, recorded that products containing melanotan II "are classified as medicines if they are injectable or pens," and that it received 16 UK Yellow Card reports between 2012 and 2022. Australia's TGA issued 27 infringement notices totalling $101,412 on 21 May 2026. Denmark's Lægemiddelstyrelsen warned in 2008 and again on 20 June 2011.

That five-agency record exists for melanotan II and, in this corpus, for no other compound. Treat it as a demonstration of what published regulatory findings look like rather than as a template that can be assumed for peptides no agency has commented on. Where this record only carries US facts, it says so — the status of most of these compounds in Canada, Germany, Japan, India or the Gulf is not established here in either direction.

What else gets called over the counter and is not a peptide medicine?

Two adjacent regulatory categories account for most of the remaining confusion. Cosmetic ingredients require no FDA pre-approval before marketing — FDA states this explicitly — which is why a topical peptide can sit on a shelf without an approval and without being an over-the-counter drug. And dietary supplements are a separate framework again: NMN's exclusion from the dietary supplement definition was reversed on 29 September 2025, a live example of a settled regulatory position changing direction.

FDA draws the boundary by intended use rather than by product type. A product intended "to affect the structure or function of the body" is regulated as a drug even if it affects appearance. That single sentence is why a cosmetic claim and a physiological claim about the same cream land in different regulatory categories, and why marketing copy can move a product across a line the formulation never crossed.

The NMN reversal deserves its own note for a reason beyond NMN. A confident, correct-in-2024 statement that FDA had excluded NMN from the supplement definition became a false statement in September 2025, and content that was never updated is now misinforming readers. Regulatory claims need dating, which is why every date on this page is printed rather than summarised — see NAD boosters for that specific record.

Which claims about buying peptides over the counter survive the record?

Two of nine. Some peptides genuinely hold over-the-counter status in a national register, and cosmetic ingredients genuinely need no FDA pre-approval. Everything else on the usual list fails: that a research label makes a sale lawful, that absence from FDA's compounding lists is permission, that the July 2026 advisory votes changed a legal status, that compounded means over-the-counter, and that a Russian registration transfers to any other country.

How do you check which category a compound is in?

Four documents, in order, and none of them requires a subscription. Search FDA's drug application and novel approvals records for an approval; check the three statutory prongs at 21 U.S.C. § 353a(b)(1)(A) for a compounding route; read both bulk substances tables on the compounding page and remember that absence is not permission; and search the relevant national medicines register for any over-the-counter listing, remembering that it binds only in that country. A seller's description is not one of the four.

The fourth row is the one that resolves the title question for any specific compound. An over-the-counter claim that cannot cite a certificate number, a marketing authorisation holder, a registered form and an ATC code is not describing a register. It is describing a shop.

What does the platform data show on the compounds that are over the counter somewhere?

Peptigrity tracks 530 shops and 11,852 independent lab tests across 118 peptides, with 1,283 community reviews (verified August 2026), with trust scores weighting community reviews and independently verified HPLC purity equally at 50% each. Selank price data shows 77 shops in stock at a median $4.50/mg, lowest $1.70/mg on a 10 mg vial, from 190 known sellers. Semax price data shows 72 shops in stock at a median $4.09/mg, lowest $1.75/mg, from 179 known sellers (both verified August 2026).

Those figures exclude shipping, taxes and customs, coupon codes, bulk tiers, multi-vial kits and account-gated pricing. Individual results are searchable in the lab test database, per-compound averages in the Purity Index, and shop-level detail on the Selank compound page and the Semax compound page.

Read that table against the category system rather than as a shopping guide. The vials this platform tracks are not the registered Russian products. The registered products are percentage solutions in nasal bottles; research-market vials are lyophilised powders labelled in milligrams, and the arithmetic between the two depends entirely on reconstitution volume. Selank's tested fill accuracy runs −10.3% to +28.6% against the label, which is a wider band than any registered medicine would tolerate. Category 4 status attaches to a registered product in one country, not to a vial shipped from anywhere.

The trial that would settle this

The category question is settled by registers and statutes rather than by evidence, so what remains open is the analytical question sitting underneath category 3 — and it is open for every compound in it at once. Nobody has published a systematic measurement of what research-market vials contain against their labels across compounds and vendors. We could find no published equivalent, which is not the same as none existing.

Frequently Asked Questions

Are any peptides sold over the counter in the United States?

Not as medicines. Every peptide in this record is either an approved prescription drug, a bulk substance that may be compounded on a prescription, or an unapproved new drug when sold for human use. Topical cosmetic ingredients are a separate framework and need no FDA pre-approval, but a product intended to affect the structure or function of the body is regulated as a drug regardless of where it is sold.

Which peptides are over the counter in Russia?

Selank is registered as a 0.15% nasal drop under certificate ЛП-№(010951)-(РГ-RU), held by JSC INPC "Peptogen" of Moscow, and dispensed without prescription — Peptogen states it became an over-the-counter medicine on 2 August 2017. Semax holds certificate ЛП-№(009449)-(РГ-RU) as 0.1% and 1% nasal drops and sits on Russia's Vital and Essential Medicines list. Neither status applies outside Russia.

Does "research use only" labelling make a peptide legal to sell?

No. FDA has warned companies selling unapproved drugs "falsely labeled 'for research purposes' or 'not for human consumption,'" and its warning letter to Xcel Research LLC on 10 December 2024 held seven products including sermorelin to be unapproved new drugs despite exactly that labelling, because website evidence established human intended use. The disclaimer described the label, not the transaction.

Did the July 2026 advisory votes make six peptides legal?

No. FDA staff recommended against all seven substances reviewed on 23 and 24 July 2026, and the committee overrode that six times, but an advisory vote is not an agency action. Nothing has been added to any list and no rulemaking has begun. FDA published no minutes or transcript, so every published tally is press-derived.

Is a compounded peptide the same as an over-the-counter one?

No. Compounding is a prescription activity: a licensed pharmacist prepares the medicine for a named patient against a valid prescription, from a bulk substance satisfying one of three statutory prongs. FDA also states plainly that compounded drugs are not FDA-approved and that it does not verify their safety, effectiveness or quality before marketing.

If a peptide is not on FDA's lists, does that mean it is allowed?

No. Most peptides were never nominated, so FDA has never evaluated them — an absence that carries no permission whatsoever. A compound nobody asked about sits in the same compounding position as one FDA examined and flagged. And of the substances that did leave the active list, FDA's own note says they "were withdrawn by the nominators," which is procedural rather than a clearance.

Where this leaves the question

The useful version of this question is not "can you buy peptides over the counter" but "which of four categories is this specific compound in, and in which country". Three of the four categories return a no, for three different reasons: an approval that requires a prescriber, a compounding route that is itself a prescription activity, and an unapproved product whose seller-side position FDA has stated in writing. The fourth returns a yes that is bounded by a border.

What that framework buys a reader is the ability to spot the two errors that dominate this market. Absence from a list is not permission, and an advisory vote is not an agency action — the July 2026 tallies changed nothing, and FDA's own note says the withdrawn substances "were withdrawn by the nominators." Everything else follows from reading a register rather than a product page.

Browse the cognitive and neuroprotective peptides category, or our complete peptide guide with 118 compounds (verified August 2026). For converting a percentage solution into a reconstituted vial concentration, use the peptide dosing calculator alongside the reconstitution calculator. Compare shops through independent lab tests and community-verified shop reviews.

This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.